Home > Annual Financials > INDEGENE

INDEGENE Financial Statement Analysis
[BOM: 544172|NSE : INDGN]

The Revenues of INDEGENE have increased by 12.29% YoY .
The Earnings Per Share (EPS) of INDEGENE has increased by 26.31 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

INDEGENE Last 5 Annual Financial Results
[BOM: 544172|NSE : INDGN]

ConsolidatedMar2024
Mar2023
Mar2022
Mar2021
Mar2020
Revenues ₹2,590 Cr₹2,306 Cr₹1,665 Cr₹966 Cr₹643 Cr
Expenses ₹2,084 Cr₹1,910 Cr₹1,378 Cr₹736 Cr₹499 Cr
Operating Profit (Excl OI) ₹505 Cr₹396 Cr₹287 Cr₹231 Cr₹144 Cr
Other Income ₹76 Cr₹58 Cr₹26 Cr₹31 Cr₹3.50 Cr
Interest ₹49 Cr₹31 Cr₹5.96 Cr₹6.96 Cr₹8.80 Cr
Depreciation ₹76 Cr₹60 Cr₹33 Cr₹26 Cr₹19 Cr
Profit Before Tax ₹459 Cr₹363 Cr₹226 Cr₹231 Cr₹75 Cr
Profit After Tax ₹337 Cr₹266 Cr₹163 Cr₹186 Cr₹49 Cr
Consolidated Net Profit ₹337 Cr₹266 Cr₹165 Cr₹149 Cr₹-6.30 Cr
Earnings Per Share (Rs)₹15.17₹12.01₹938.81₹954.66₹-40.26
PAT Margin (%)13.0011.549.7819.227.65
ROE(%)27.5629.5030.20176.320.00
ROCE(%)30.8835.2041.0968.5429.65
Total Debt/Equity(x)0.290.380.020.08-4.12

Key Financials

Market Cap : ₹ 13,226.4 Cr
Revenue (TTM) : ₹ 2,756.7 Cr
Net Profit(TTM) : ₹ 383.9 Cr
EPS (TTM) : ₹ 16.0
P/E (TTM) : 34.5

Industry Peers & Returns1W1M1Y
INDEGENE -4.7% 4.7% NA
SUN PHARMACEUTICAL INDUSTRIES -1.5% 4.6% 3%
DIVIS LABORATORIES -4.8% -3.2% 40.7%
CIPLA -1.3% -1.9% -5.2%
TORRENT PHARMACEUTICALS 1.1% 6.1% 27.1%
DR REDDYS LABORATORIES -3.6% -2.7% -11.4%
MANKIND PHARMA -3.2% 3% 2%
ZYDUS LIFESCIENCES -3.6% -5.2% -14.9%
LUPIN -1.3% -1.8% 21.2%


INDEGENE Revenues
[BOM: 544172|NSE : INDGN]

Y-o-Y

12.29 %

5 Yr CAGR

41.67 %

Years Revenues % Change
Mar2024 ₹2,590 Cr
12.29
Mar2023 ₹2,306 Cr
38.54
Mar2022 ₹1,665 Cr
72.27
Mar2021 ₹966 Cr
50.30
Mar2020 ₹643 Cr -


INDEGENE Operating Profit
[BOM: 544172|NSE : INDGN]

Y-o-Y

27.66 %

5 Yr CAGR

36.97 %

Years Operating Profit % Change
Mar2024 ₹505 Cr
27.66
Mar2023 ₹396 Cr
37.98
Mar2022 ₹287 Cr
24.46
Mar2021 ₹231 Cr
60.54
Mar2020 ₹144 Cr -

Operating Margins
Y-o-Y

13.69 %

5 Yr CAGR

-3.32 %

Years Operating Margin% % Change
Mar2024 19.52%
13.69
Mar2023 17.17%
-0.41
Mar2022 17.24%
-27.75
Mar2021 23.86%
6.80
Mar2020 22.34% -

INDEGENE Profit After Tax
[BOM: 544172|NSE : INDGN]

Y-o-Y

26.53 %

5 Yr CAGR

Positive

Years Profit After Tax % Change
Mar2024 ₹337 Cr
26.53
Mar2023 ₹266 Cr
61.51
Mar2022 ₹165 Cr
10.28
Mar2021 ₹149 Cr
Positive
Mar2020 ₹-6.30 Cr -

PAT Margins
Y-o-Y

12.65 %

5 Yr CAGR

14.17 %

Years PAT Margin(%) % Change
Mar2024 13 %
12.65
Mar2023 11.54 %
18.00
Mar2022 9.78 %
-49.12
Mar2021 19.22 %
151.24
Mar2020 7.65 % -

INDEGENE Earnings Per Share (EPS)
[BOM: 544172|NSE : INDGN]

Y-o-Y

26.31 %

5 Yr CAGR

Positive

Years EPS % Change
Mar2024 ₹15
26.31
Mar2023 ₹12
-98.72
Mar2022 ₹939
-1.66
Mar2021 ₹955
Positive
Mar2020 ₹-40 -

INDEGENE Return on Capital Employed (ROCE)
[BOM: 544172|NSE : INDGN]

Y-o-Y

-12.27 %

5 Yr CAGR

1.02 %

Years ROCE % Change
Mar2024 30.88%
-12.27
Mar2023 35.2%
-14.33
Mar2022 41.09%
-40.05
Mar2021 68.54%
131.16
Mar2020 29.65% -

INDEGENE Share Price vs Sensex

Current Share Price : ₹551.1
Current MarketCap: ₹ 13,226.4 Cr
Updated EOD on :Apr 08,2025

Share Price Returns(%) 1 Week 1 Month 1 Year
INDEGENE

-4.7%

4.7%

NA
SENSEX

-2.4%

0.7%

0.5%

INDEGENE related INDICES

BSE Indices1W1M1Y
BSE HEALTHCARE -1.9% 2% 12.9%
BSE SELECT IPO INDEX -2.1% 1.6% NA
BSE MIDSMALLCAP -3.4% 0.6% -1.7%
BSE SMALLCAP -3.7% 0.9% -1.4%
BSE IPO -4.3% -3.2% -6%
NSE Indices1W1M1Y
NIFTY 500 -2.8% 1.1% -0.6%
NIFTY TOTAL MARKET -2.8% 1% -0.6%
NIFTY500 MULTICAP 50:25:25 -3% 1.1% -0.8%
NIFTY MIDSMALLCAP 400 -3.1% 1% -1.3%
NIFTY SMALLCAP 250 -3.5% 1.5% -3.8%

You may also like the below Video Courses


FAQ about INDEGENE Financials


How the annual revenues of INDEGENE have changed ?

The Revenues of INDEGENE have increased by 12.29% YoY .

How the Earnings per Share (EPS) of INDEGENE have changed?

The Earnings Per Share (EPS) of INDEGENE has increased by 26.31 % YoY .